Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO1105 RSV mRNA vaccine in adults 50+
NCT07289542Phase 2Active, not recruiting
- Sponsor
- Abogen Bioscience
- Start
- Sep 2025
- Primary completion
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ABO1105 in respiratory syncytial virus infection (RSV), sponsored by Abogen Bioscience. Started Sep 2025; status: active, not recruiting.
02
Drugs
ABO1105
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07289542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07289542.